RxDoctor Payments Data

Ima Ebong, MD

Clinical Neurophysiology · Lexington, KYNPI 1891037230

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,000 of the $11,555 with a category attached, or 77.9%. UCB, Inc. accounts for 84.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $9,286 and has fallen 98.8% since, to $112 in 2025.

$11,555in general payments, 2019–2025

Across 119 payments — averaging $97.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$10K
  • CSL Behring$546
  • Akcea Therapeutics, Inc.$244
  • Eisai Inc.$164
  • Jazz Pharmaceuticals Inc.$118
  • AstraZeneca$108
  • plus $652 from 14 others
$3,120in research payments, 2019–2025

Across 2 payments — averaging $1560.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB, Inc.$3K

What the payments were for

  • Consulting fees$9,00078%
  • Food & beverage$2,54122%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$19,067
Medicare patients
112
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumizymeAlglucosidase Alfa26$722,771
VyvgartEfgartigimod Alfa-Fcab23$364,261
BriviactBrivaracetam17$23,210
Nurtec OdtRimegepant Sulfate11$21,623
FycompaPerampanel19$21,274
AptiomEslicarbazepine Acetate13$19,755
NayzilamMidazolam11$7,033
Levetiracetam55$1,773
Oxcarbazepine20$1,505
Mycophenolate Mofetil22$1,469
Lacosamide12$1,145
Clobazam16$1,022
Phenobarbital35$875
Pyridostigmine Bromide15$727
Gabapentin40$446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$46$364,26123 claims
UCB, Inc.Briviact, Nayzilam$9,723$30,24328 claims
Eisai Inc.Fycompa$164$21,27419 claims
Sunovion Pharmaceuticals Inc.Aptiom$58$19,75513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →